Story perspectives

FDA Vaccine Chief Resigns Amid Controversy and Industry Relief

3/9/2026

Summary

Story summary

Dr. Vinay Prasad, head of the FDA's vaccine division, will resign at the end of April to return to the University of California, San Francisco.
His tenure has drawn controversy over decisions on COVID-19 vaccines and gene therapies.
FDA Commissioner Marty Makary praised Prasad's accomplishments but noted backlash.
Prasad faced scrutiny over his management and decisions.
Biotech shares surged after the announcement, signaling industry relief.

History

Historical Context

The FDA's COVID-19 vaccine approvals in 2021 faced scrutiny, echoing past criticisms of the agency's regulatory practices. Dr. Peter Marks led the emergency use authorization, with over 300 million doses administered by mid-year. The resignation of Dr. Vinay Prasad highlighted ongoing debates about vaccine safety, reflecting historical tensions in public health policy and the biotech industry's reliance on regulatory decisions for market stability.

1 of 2

Story summary

Dr. Vinay Prasad, head of the FDA's vaccine division, will resign at the end of April to return to the University of California, San Francisco.
His tenure has drawn controversy over decisions on COVID-19 vaccines and gene therapies.
FDA Commissioner Marty Makary praised Prasad's accomplishments but noted backlash.
Prasad faced scrutiny over his management and decisions.
Biotech shares surged after the announcement, signaling industry relief.

1 / 2